Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer

详细信息    查看全文

• 作者：Barbro K. Linderholm ; Sofia Gruvbreger-Saal ; Må ; rten Fernö ; Pä ; r-Ola Bendahl ; Per Malmströ ; m
• 关键词：Vascular endothelial growth factor (VEGF) ; Urokinase-type plasminogen activator (uPA) ; S-phase fraction (SPF) ; Early relapses ; Premenopausal lymph node-negative breast cancer
• 刊名：The Breast
• 出版年：2008
• 出版时间：October 2008
• 年：2008
• 卷：17
• 期：5
• 页码：484-491
• 全文大小：225 K

文摘

We investigate the prognostic significance of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and S-phase fraction (SPF) for distant disease free survival (DDFS) in 219 premenopausal patients with node-negative breast cancer (NNBC). In univariate analysis significantly shorter DDFS was observed for patients with high VEGF (p = 0.006), high uPA (p = 0.001), and high SPF (p < 0.001). The prognostic significance of VEGF varied over time being very strong for early relapses (0–2.25 years follow-up) (HR = 7.9; p = 0.006) while no difference was seen in the subsequent follow-up period (HR = 1.3; p = 0.62). In a series of bivariate analyses VEGF provided prognostic information during the whole observation period (0–72 months) in addition to age, tumour size, oestrogen receptor (ER), progesterone receptor (PgR), and uPA. Also this effect was more pronounced during the first follow-up period suggesting VEGF as a marker of early recurrences.